Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04826198
Title Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib (REVOCAN)
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris

peritoneum cancer

fallopian tube cancer

ovarian cancer


AsiDNA + Niraparib

Age Groups: senior | adult
Covered Countries FRA

No variant requirements are available.